Premium
Hormonal effects and metabolic clearance rate of the enkephalin analogue DAMME in man.
Author(s) -
Gilchrist N,
Bolton JE,
Donald RA,
Livesey JH,
Roud HK,
Nicholls MG
Publication year - 1983
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1983.tb02201.x
Subject(s) - prolactin , endocrinology , medicine , radioimmunoassay , hormone , glucagon , chemistry , hydrocortisone , growth hormone , saline
The enkephalin analogue DAMME (0.25 mg) and normal saline were administered by slow intravenous injection to six normal male subjects in a double‐blind crossover study. Plasma DAMME concentrations were measured by a specific radioimmunoassay. A significant rise in plasma growth hormone and prolactin and a significant fall in plasma corticotrophin and cortisol concentrations were observed. The fall in pancreatic polypeptide concentration just failed to reach significance. No significant changes were observed in insulin, glucagon, glucose, adrenaline and noradrenaline. Serum concentrations of DAMME were initially high (greater than 6.7 nmol/1) corresponding with the observed maximum plasma growth hormone and prolactin responses. The serum DAMME concentration was readily detectable when plasma growth hormone and prolactin had returned to control levels, but corticotrophin and cortisol were still significantly depressed.